Please login to the form below

Not currently logged in

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone


Novartis has positive phase III results in hand for its PI3K inhibitor alpelisib in advanced breast cancer patients, which it hopes will be enough to file for regulatory approvals.

The SOLAR-1 trial compared alpelisib (BYL719) plus hormonal therapy fulvestrant to fulvestrant alone as a second-line therapy for patients with hormone receptor-positive/HER2-negative breast cancer whose tumours also had PIK3CA mutations

The two regimens were compared in patients whose cancer had progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor such as Pfizer’s Ibrance (palbociclib), Novartis’ own Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib). Those who were treated with alpelisib had longer progression-free survival than those on fulvestrant alone.

“We…look forward to submitting the data to an upcoming medical congress and starting discussions with health authorities worldwide,” commented Samit Hirawat, Novartis’ head of oncology drug development.

At the moment no PI3K inhibitor has been approved for use in breast cancer, although Gilead Sciences’ Zydelig (idelalisib) has been used for certain types of leukaemia and lymphoma for several years and was recently joined on the market by Bayer’s Aliqopa (copanlisib), also for blood cancers. Zydelig has been affected by safety concerns, particularly the risk of severe infections, that have pegged back its sales.

Novartis has been in the forefront of the race to develop PI3K inhibitors for solid tumours, along with fellow Swiss drugmaker Roche which reported data from the SANDPIPER trial of its taselisib candidate alongside fulvestrant at this year’s American Society of Clinical Oncology (ASCO) meeting.

With nothing but the top-line message from SOLAR-1 available just yet it’s hard to gauge the prospects for alpelisib, but it is worth noting that SANDPIPER raised a lot of questions about the role of PI3K in breast cancer, particularly as taselisib’s extended PFS modestly (from 5.4 months to 7.4 months) and was associated with a serious hike in side effects.

Novartis said the adverse events observed with alpelisib in combination with fulvestrant in SOLAR-1 “were generally consistent with those observed in previous … studies” of the combination.

Hirawat said that alpelisib is the only PI3K inhibitor that acts specifically at the alpha receptor and “the first one to show potential increased benefit and acceptable tolerability for patients.”

In a statement, Novartis said that activation of the PI3K pathway in breast cancer is associated with resistance to endocrine therapy, disease progression and poorer prognosis. Approximately 40% of HR+ advanced breast cancer patients have PIK3CA mutations involving the alpha isoform.

Article by
Phil Taylor

23rd August 2018

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change